Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
about
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitusAspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treAtherosclerosis, cholesterol, nutrition, and statins--a critical reviewDiabetes is a proinflammatory state: a translational perspective.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Therapeutic interventions and oxidative stress in diabetesRosuvastatin restored adrenergic and nitrergic function in mesenteric arteries from obese rats.Extreme values of hemoglobin a1c are associated with increased risks of chronic obstructive pulmonary disease in patients with type 2 diabetes: a competing risk analysis in national cohort of Taiwan diabetes study.Flow-Mediated Vasodilatation and Intima-Media Thickness in Patients with Coexisting Heart Failure and Diabetes Receiving Medical Therapy.The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients.Effects of systemic inflammation on endothelium-dependent vasodilationRenin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics.Pitavastatin: finding its place in therapy.The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation.A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.Cohort profile: the German Diabetes Study (GDS).Impaired retinal vasodilator responses in prediabetes and type 2 diabetes.A useful predictor of early atherosclerosis in obese children: serum high-sensitivity C-reactive protein.Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE studySerum myeloperoxidase levels independently predict endothelial dysfunction in humans.Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical TrialInflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype.The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.Impaired systemic vascular reactivity & raised high-sensitivity C reactive protein levels in chronic obstructive pulmonary disease.Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, non-smoker subjects without hypertension.Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease.Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.Endothelial Dysfunction in Type 2 Diabetes Mellitus.Statins and micronutrients: unanswered questions
P2860
Q24804153-7FE4903B-F46E-44F7-A532-A183017BD0F8Q28219328-EDD5355B-3B78-4D80-A087-F80FE595B59AQ28220363-D8BC0E13-018D-4F24-B0B2-09D88977BD8DQ30379837-8814881A-D6A9-4A26-B1A3-05B5C73D5BEAQ33693974-217C4E6B-77A0-47CF-BEF0-A21DE8C68763Q33776230-F163A412-8B87-4BDC-AFC8-907FD66C5161Q33870395-4066A1F7-6EB5-45F1-9C3F-17B5B536A9F9Q34449768-A67BF74F-7C11-44D9-BD96-81B758E5CCF6Q36152781-AEFDE3B0-6FE4-4B7C-A354-17ED13044AEBQ36334981-5DA675E6-8006-4265-8760-0451589D1DCCQ36347868-031F290F-D6EC-4032-9F91-AFA4C8FEEF16Q36357765-57DA2914-F96A-48F9-A899-43481954606DQ36410456-567EFF18-CFFB-4986-AC7E-59BAE7BE9A4FQ36443716-4A2DA25F-377D-40D5-9380-F7FE97C69F76Q36536154-084A8CC7-05C4-429F-B94F-76FCDD051145Q36697677-B3BDDD57-CE6E-42F7-BF94-9E0D9F360FE2Q36774677-0FE8C391-62C8-4E99-A463-9962951EA73FQ37110310-DB994F32-E7D3-4104-9C5A-28A647B7C793Q37220318-7BAC7015-9611-4144-AA40-62A861E47DB4Q37254915-A4332604-F837-4EEE-8B2D-D27D9DFED41CQ37281608-B0DDA75B-2C72-48E4-A7D8-E5514D9AA3B7Q37316891-4DB50815-2804-4CB0-87FB-097DD6F517C3Q37581259-CB78F8AA-1A89-4B19-8B38-8B1D326A5D71Q37726715-B887B299-D450-4C46-A54A-AA015A17F6B6Q38874977-D3C19D6C-39BD-4367-84D0-DDB0188AFB1CQ40038797-A5FA0570-7074-4325-91C2-2EFFFCF1F104Q43202813-C67D24BD-F74A-486F-AEE7-AC80A43C1FC1Q44904267-6632F1E7-9DF1-4F93-91A9-BC56D01454FBQ46331113-AADE5D2A-CC0C-4BC0-B2F3-412EC3D46CBEQ46422677-8527AAD8-3142-4C9E-A6D0-AD579A656D18Q46879881-4DC9E02E-EDE7-493D-AAF6-355047936CCAQ46885814-35778D91-E768-4B75-B3CA-384BD04C5C24Q52674867-DD634ECF-992B-483D-81BA-01D460B38E20Q57766255-730455EB-24B2-4375-A068-62963D6A2186
P2860
Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@en
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@nl
type
label
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@en
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@nl
prefLabel
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@en
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@nl
P2093
P356
P1476
Atorvastatin lowers C-reactive ...... n in type 2 diabetes mellitus.
@en
P2093
P304
P356
10.1210/JC.87.2.563
P407
P577
2002-02-01T00:00:00Z